Solubility based mechanistic profiling of combinatorial drug therapy
Published version of a preprint
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A subset of DORSSAA directly derives from our recent combinatorial therapy study in 4 AML cell lines and includes 4 single drugs and 2 drug combinations (20, 21).”
From DORSSAA: Drug-Target interactOmics Resource Based on Stability/Solubility Alteration Assay (2026) · cites this paper as [21]
In the citing paper
“We assembled a harmonized corpus of 24 publicly available thermal-shift proteomics datasets, covering TPP, PISA, and i-PISA, together with our in-house CoPISA dataset (20, 20, 21).”
From DORSSAA: Drug-Target interactOmics Resource Based on Stability/Solubility Alteration Assay (2026) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tracking cancer drugs in living cells by thermal profiling of the proteome
Savitski, M. M., Reinhard, F. B. M., Franken, H., Werner, T., Savitski, M. F., Eberhard, D., Molina, D. M., Jafari, R., Dovega, R. B., Klaeger, S., et al. (2014) · Science · doi:10.1126/science.1255784 · Cited by 1,187
The present and future of the Cancer Dependency Map
Arafeh, R., Shibue, T., Dempster, J. M., Hahn, W. C., & Vazquez, F. (2025) · Nature Reviews Cancer · doi:10.1038/s41568-024-00763-x · Cited by 454
Proteome Integral Solubility Alteration: A High-Throughput Proteomics Assay for Target Deconvolution
Gaetani, M., Sabatier, P., Saei, A. A., Beusch, C. M., Yang, Z., Lundström, S. L., & Zubarev, R. A. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00500 · Cited by 287 · cited 3×
“The thermal shift assays leverage the principle that drug binding affects the solubility or thermodynamic stability of a protein, allowing researchers to identify drug targets across the whole cellular proteome 12 .”
Self-citationSHP2 sails from physiology to pathology
Tajan, M., de Rocca Serra, A., Valet, P., Edouard, T., & Yart, A. (2015) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2015.08.005 · Cited by 232 · cited 1×
“Among these, PTPN11, encoding the SHP2 phosphatase frequently mutated in myeloid malignancies, suggests inhibition of RAS/MAPK pathway signaling critical for leukemic cell maintenance 18 .”
Methods for High-throughput Drug Combination Screening and Synergy Scoring
He, L., Kulesskiy, E., Saarela, J., Turunen, L., Wennerberg, K., Aittokallio, T., & Tang, J. (2018) · Methods in Molecular Biology · doi:10.1007/978-1-4939-7493-1_17 · Cited by 232
Multiple testing corrections in quantitative proteomics: A useful but blunt tool
Pascovici, D., Handler, D. C. L., Wu, J. X., & Haynes, P. A. (2016) · PROTEOMICS · doi:10.1002/pmic.201600044 · Cited by 218 · cited 1×
“Due to the complexity of comparing single drugs and combinations in the CoPISA method and the lack of an a priori error model in a low-power proteomics context 71 , direct multiple hypothesis correction was not feasible.”
Self-citationImplementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
Malani, D., Kumar, A., Brück, O., Kontro, M., Yadav, B., Hellesøy, M., Kuusanmäki, H., Dufva, O., Kankainen, M., Eldfors, S., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0410 · Cited by 193
Self-citationChen, Y., Ouyang, Y., Li, Z., Wang, X., & Ma, J. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188891 · Cited by 165
DORSSAA: Drug-Target interactOmics Resource Based on Stability/Solubility Alteration Assay
Zangene, E., Gholizadeh, E., Schwämmle, V., Saei, A. A., Wilhelm, M., Käll, L., & Jafari, M. (2026) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2026.101603 · Cited by 3
Self-citation
Research works printed but not linked: 67
- Döhner, K., Paschka, P. & Döhner, H. [Acute myeloid leukemia]. Internist 56, 354–363 (2015). · DOI
- Cherry, E. M. et al. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 5, 5565–5573 (2021). · DOI · Paper page
- Karol, S. E. et al. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. Lancet Oncol. 21, 551–560 (2020). · DOI · Paper page
- Mason-Osann, E., Pomeroy, A. E., Palmer, A. C. & Mettetal, J. T. Synergistic Drug Combinations Promote the Development of Resistance in Acute Myeloid Leukemia. Blood Cancer Discov. 5, 95–105 (2024). · DOI
- Tyner, J. et al. Functional genomic landscape of acute myeloid leukemia. Nature 562, 526–531 (2018). · DOI · Paper page
- Tang, K., Schuh, A. C. & Yee, K. W. 3+7 Combined chemotherapy for acute myeloid leukemia:is it time to say goodbye? Curr. Oncol. Rep. 23, 120 (2021). · DOI
- Wang, J., Tomlinson, B. & Lazarus, H. M. Update on small molecule targeted therapies for acute myeloid leukemia. Curr. Treat. Options Oncol. 24, 770–801 (2023). · DOI
- Mirzaie, M. et al. Designing patient-oriented combination therapies for acute myeloid leukemia based on efficacy/toxicity integration and bipartite network modeling. Oncogenesis 13, 11 (2024). · DOI · Paper page
- Gholizadeh, E. et al. Targeting acute myeloid leukemia resistance with two novel combinations demonstrate superior efficacy in TP53, HLA-B, MUC4 and FLT3 mutations. Biomed. Pharmacother. 192, 118647 (2025). · DOI
- Mateus, A., Määttä, T. A. & Savitski, M. M. Thermal proteome profiling: unbiased assessment of protein state through heat-induced stability changes. Proteome Sci. 15, 13 (2016). · DOI · Paper page
- Saei, A. A. et al. Multifaceted proteome analysis at solubility, redox, and expression dimensions for target identification. Adv. Sci. 11, e2401502 (2024). · DOI
- Van Vranken, J. G. et al. Large-scale characterization of drug mechanism of action using proteome-wide thermal shift assays. eLife 13, RP95595 (2024). · DOI
- Franken, H. et al. Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry. Nat. Protoc. 10, 1567–1593 (2015). · DOI · Paper page
- Jafari, M., Ansari-Pour, N., Azimzadeh, S. & Mirzaie, M. A logic-based dynamic modeling approach to explicate the evolution of the central dogma of molecular biology. PLoS ONE 12, e0189922 (2017). · DOI
- Tian, C. et al. UCHL1 promotes cancer stemness in triple-negative breast cancer. Pathol. Res. Pract. 240, 154235 (2022). · DOI
- Meng, Y. et al. Research advances in the role of the tropomyosin family in cancer. Int. J. Mol. Sci. 24, 13295 (2023). · DOI
- Estecha, A., Aguilera-Montilla, N., Sánchez-Mateos, P. & Puig-Kröger, A. RUNX3 regulates intercellular adhesion molecule 3 (ICAM−3) expression during macrophage differentiation and monocyte extravasation. PLoS ONE 7, e33313 (2012). · DOI
- Greuber, E. K., Smith-Pearson, P., Wang, J. & Pendergast, A. M. Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat. Rev. Cancer 13, 559–571 (2013). · DOI · Paper page
- Carter, J. L. et al. Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduct. Target. Ther. 5, 288 (2020). · DOI · Paper page
- Bottani, E. et al. TTC19 plays a husbandry role on UQCRFS1 turnover in the biogenesis of mitochondrial respiratory complex III. Mol. Cell 67, 96–105 (2017). · DOI
- Borkar, R. M. et al. An evaluation of the CYP2D6 and CYP3A4 inhibition potential of metoprolol metabolites and their contribution to drug-drug and drug-herb interaction by LC-ESI/MS/MS. Biomed. Chromatogr. 30, 1556–1572 (2016). · DOI
- Müller, S., Ledl, A. & Schmidt, D. SUMO: a regulator of gene expression and genome integrity. Oncogene 23, 1998–2008 (2004). · DOI · Paper page
- Ghelli Luserna di Rorà, A., Martinelli, G. & Simonetti, G. The balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window? J. Hematol. Oncol. 12, 123 (2019). · DOI
- Cheng, Y. et al. Tumor microenvironmental competitive endogenous RNA network and immune cells act as robust prognostic predictor of acute myeloid leukemia. Front. Oncol. 11, 584884 (2021). · DOI
- Trombetti, S. et al. Oxidative stress and ROS-mediated signaling in leukemia: Novel promising perspectives to eradicate chemoresistant cells in myeloid leukemia. Int. J. Mol. Sci. 22, 2470 (2021). · DOI
- Addanki, S., Kim, L. E. & Stevens, A. M. Understanding and targeting metabolic vulnerabilities in acute myeloid leukemia: An updated comprehensive review. Cancers17, (2025). · DOI
- Saraon, P. et al. Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches. Oncogene 40, 4079–4093 (2021). · DOI · Paper page
- Tettamanti, S., Pievani, A., Biondi, A., Dotti, G. & Serafini, M. Catch me if you can: how AML and its niche escape immunotherapy. Leukemia 36, 13–22 (2021). · DOI · Paper page
- Pabst, T. & Mueller, B. Transcriptional dysregulation during myeloid transformation in AML. Oncogene 26, 6829–6837 (2007). · DOI
- Biffo, S., Ruggero, D. & Santoro, M. M. The crosstalk between metabolism and translation. Cell Metab. 36, 1945–1962 (2024). · DOI
- Crews, L. A. et al. RNA splicing modulation selectively impairs leukemia stem cell maintenance in secondary human AML. Cell Stem Cell 19, 599–612 (2016). · DOI · Paper page
- Chen, C. & Zhang, J. Enhancing leukemia treatment: The role of combined therapies based on amino acid starvation. Cancers16, 1171 (2024). · DOI
- Ciciarello, M., Corradi, G., Forte, D., Cavo, M. & Curti, A. Emerging bone marrow microenvironment-driven mechanisms of drug resistance in acute myeloid leukemia: Tangle or chance? Cancers13, 5319 (2021). · DOI
- Teague, R. M. & Kline, J. Immune evasion in acute myeloid leukemia: current concepts and future directions. J. Immunother. Cancer 1, 13 (2013). · DOI
- Fan, C., Yang, X., Yan, L. & Shi, Z. Oxidative stress is two-sided in the treatment of acute myeloid leukemia. Cancer Med. 13, e6806 (2024). · DOI
- Yates, L. A., Zhang, X. & Burgers, P. M. DNA damage and replication stress checkpoints. Annu. Rev. Biochem. 94, 195–221 (2025). · DOI
- Weisberg, E. et al. Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia 34, 625–629 (2020). · DOI
- Nickchi, P. et al. Monitoring functional posttranslational modifications using a data-driven proteome informatic pipeline. Proteomics 25, e202400238 (2025). · DOI
- Liu, X. et al. Sumoylation of nucleophosmin/B23 regulates its subcellular localization, mediating cell proliferation and survival. Proc. Natl. Acad. Sci. USA 104, 9679–9684 (2007). · DOI
- Shandilya, J. et al. Acetylated NPM1 localizes in the nucleoplasm and regulates transcriptional activation of genes implicated in oral cancer manifestation. Mol. Cell. Biol. 29, 5115–5127 (2009). · DOI
- Langland, G. et al. The BLM helicase is necessary for normal DNA double-strand break repair. Cancer Res. 62, 2766–2770 (2002).
- Wang, Y. & Luo, J. Acetylation of BLM protein regulates its function in response to DNA damage. RSC Adv. 7, 55301–55308 (2017). · DOI
- Ouyang, K. J., Yagle, M. K., Matunis, M. J. & Ellis, N. A. BLM SUMOylation regulates ssDNA accumulation at stalled replication forks. Front. Genet. 4, 167 (2013). · DOI
- Pomeroy, A. E., Schmidt, E. V., Sorger, P. K. & Palmer, A. C. Drug independence and the curability of cancer by combination chemotherapy. Trends Cancer Res. 8, 915–929 (2022). · DOI · Paper page
- Arnone, M. et al. Acute myeloid leukemia stem cells: The challenges of phenotypic heterogeneity. Cancers12, 3742 (2020). · DOI
- Filì, C. et al. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience. Leuk. Res. 76, 33–38 (2019). · DOI
- Palma, A. et al. Integrating patient-specific information into logic models of complex diseases: Application to acute myeloid leukemia. J. Pers. Med. 11, 117 (2021). · DOI
- Price, J. L. et al. Context-dependent effects of asparagine glycosylation on Pin WW folding kinetics and thermodynamics. J. Am. Chem. Soc. 132, 15359–15367 (2010). · DOI
- Jayavelu, A. K. et al. The proteogenomic subtypes of acute myeloid leukemia. Cancer Cell 40, 301–317 (2022). · DOI
- Bliss, C. I. The toxicity of poisons applied jointly1. Ann. Appl. Biol. 26, 585–615 (1939). · DOI · Paper page
- de Oliveira Lisboa, M., Brofman, P., Schmid-Braz, A. T., Rangel-Pozzo, A. & Mai, S. Chromosomal instability in acute myeloid leukemia. Cancers13, 2655 (2021). · DOI
- Guan, L. et al. Regulation of the tumor immune microenvironment by cancer-derived circular RNAs. Cell Death Dis. 14, 132 (2023). · DOI
- Chen, Y., Chen, J., Zou, Z., Xu, L. & Li, J. Crosstalk between autophagy and metabolism: implications for cell survival in acute myeloid leukemia. Cell Death Discov. 10, 46 (2024). · DOI
- Wallwitz, J., Aigner, P. & Stoiber, D. Tumor suppressors in acute myeloid leukemia. Leuk. Lymphoma 62, 2320–2330 (2021). · DOI
- Ley, T. J. et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363, 2424–2433 (2010). · DOI · Paper page
- Woods, B. A. & Levine, R. L. The role of mutations in epigenetic regulators in myeloid malignancies. Immunol. Rev. 263, 22–35 (2015). · DOI · Paper page
- Falini, B., Sportoletti, P. & Martelli, M. P. Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. Curr. Opin. Oncol. 21, 573–581 (2009). · DOI
- Barbosa, K., Li, S., Adams, P. D. & Deshpande, A. J. The role of TP53 in acute myeloid leukemia: Challenges and opportunities. Genes Chromosomes Cancer 58, 875–888 (2019). · DOI
- Cuartero, S., Innes, A. J. & Merkenschlager, M. Towards a better understanding of cohesin mutations in AML. Front. Oncol. 9, 867 (2019). · DOI
- Steelman, L. S. et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia 25, 1080–1094 (2011). · DOI · Paper page
- Leuchtmann, A. B., Afifi, Y., Ritz, D. & Handschin, C. Effects of high-resistance wheel running on hallmarks of endurance and resistance training adaptations in mice. Physiol. Rep. 11, e15701 (2023). · DOI
- Saei, A. A. et al. Mapping the GALNT1 substrate landscape with versatile proteomics tools. https://doi.org/10.1101/2022.08.24.505189. (2022) · DOI
- Saei, A. A. et al. System-wide identification and prioritization of enzyme substrates by thermal analysis. Nat. Commun. 12, 1296 (2021). · DOI
- Sabatier, P. et al. An integrative proteomics method identifies a regulator of translation during stem cell maintenance and differentiation. Nat. Commun. 12, 6558 (2021). · DOI
- Deutsch, E. W. et al. The ProteomeXchange consortium at 10 years: 2023 update. Nucleic Acids Res. 51, D1539–D1548 (2023). · DOI · Paper page
- Perez-Riverol, Y. et al. The PRIDE database at 20 years: 2025 update. Nucleic Acids Res. 53, D543–D553 (2025). · DOI · Paper page
- Perez-Riverol, Y. et al. PRIDE Inspector toolsuite: moving toward a universal visualization tool for proteomics data standard formats and quality assessment of poteomeXchange datasets. Mol. Cell Proteom. 15, 305–317 (2016). · DOI · Paper page
Cited by
DORSSAA: Drug-Target interactOmics Resource Based on Stability/Solubility Alteration Assay
Zangene, E., Gholizadeh, E., Schwämmle, V., Saei, A. A., Wilhelm, M., Käll, L., & Jafari, M. (2026) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2026.101603 · Cited by 3
Self-citation
Metadata
- Authors
- Gholizadeh, E., Zangene, E., Vadadokhau, U., Ritz, D., Miettinen, J. J., Soliymani, R., Baumann, M., Wilhelm, M., Kankuri, E., Haynes, P. A., Heckman, C. A., Saei, A. A., & Jafari, M.
- ORCID
- Venue
- Nature Communications
- Published
- 2026-03-25
- Volume
- 17
- Issue
- 1
- ISSN
- 2041-1723
- Cited by
- 5
- References
- 9
- Language
- en
- Licence
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Funders
- Academy of Finland (332454)
- Jane ja Aatos Erkon Säätiö (220031)
- Sigrid Juséliuksen Säätiö
- Syöpäsäätiö (4709178)
- Cancerfonden (243595 Pj)
- Vetenskapsrådet (2023-02692)
- Jeanssons Stiftelser (J2023-0094)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Solubility based mechanistic profiling of combinatorial drug therapy. https://app.cochat.ai/papers/10.1038/s41467-026-70394-3
- The paper
- Gholizadeh, E., Zangene, E., Vadadokhau, U., Ritz, D., Miettinen, J. J., Soliymani, R., Baumann, M., Wilhelm, M., Kankuri, E., Haynes, P. A., Heckman, C. A., Saei, A. A., & Jafari, M. (2026). Solubility based mechanistic profiling of combinatorial drug therapy. Nature Communications. https://doi.org/10.1038/s41467-026-70394-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.